Clinical and endoscopic improvement of pediatric pouchitis with ustekinumab

Key Points

Ustekinumab shows significant clinical improvement in pediatric pouchitis, enhancing patient outcomes.
Key evidence includes endoscopic improvements noted during treatment, demonstrating effective intervention.
Observational analysis across various pediatric cases highlights the safety and efficacy of ustekinumab.
The findings suggest ustekinumab as a promising therapy for pediatric pouchitis, although further studies may be necessary.],

Abstract

IT received honoraria from Takeda Pharmaceutical Corporation and AbbVie GK. HS received honoraria from Takeda Pharmaceutical Corporation and AbbVie GK and research grants from AbbVie GK. KA received honoraria from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Corporation, and AbbVie GK. KA also received consulting fees and research grants from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Corporation, and AbbVie GK. The remaining authors have no conflicts of interest to declare. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Clinical and endoscopic improvement of pediatric pouchitis with ustekinumab

Key Points

Abstract

Cite This Study